In breast cancer, mutations in individual components in the PI3K/Akt/mTOR pathway are more frequent than in the MAPK/ERK pathway [38], and this may be one reason why earlier effects were seen in the PI3K/Akt/mTOR pathway relative to the MAPK/ERK pathway. Here, AKT1 is linked to breast carcinoma.